ATN 161 is a alpha5 beta1 integrin receptor antagonist that also binds to several other integrins, including alpha5 beta1 and alphav beta3. ATN 161 is a 5-mer capped peptide derived from the synergy region (PHSRN) of human fibronectin, in which a cysteine residue replaces an arginine in the original sequence (PHSCN). ATN 161 has been shown to inhibit tumour growth, angiogenesis and metastasis and extend survival in multiple animal tumours, it has also shown activity outside oncology and can regress established Crohns disease in several animal models.
